1 |
Li, X. and Choi J. S. (2007). Effect of genistein on the pharmacokinetics
of paclitaxel administered orally or intravenously
in rats. Int. J. Pharm. 337, 188-193.
DOI
|
2 |
Meerum Terwogt, J. M., Malingre, M. M., Beijnen, J. H., ten
Bokkel Huinink, W. W., Rosing, H., Koopman, F. J., van
Tellingen, O., Swart, M. and Schellens, J. H. (1999). Coadministration
of oral cyclosporin A enables oral therapy with
paclitaxel. Clin. Cancer Res. 5, 3379-3384.
|
3 |
Nafisi, S., Hashemi, M. and Rajabi, M. (2008). DNA Adducts
with Antioxidant Flavonoids: Morin, Apigenin, and Naringin.
DNA and Cell Biology 27, 1-10.
DOI
|
4 |
Nguyen, H., Zhang, S. and Morris, M. E. (2003). Effect of
flavonoids on MRP1-mediated transport in Panc-1 cells. J.
Pharm. Sci. 92, 250-257.
DOI
|
5 |
Rahman, A., Korzekwa, K. R., Grogan, J., Gonzalez, F. J. and
Harris, J. W. (1994). Selective biotransformation of taxol to 6
alpha-hydroxytaxol by human cytochrome P450 2C8.
Cancer Res. 54, 5543-5546.
|
6 |
Rowinsky, E. K., Eisenhauer, E. A., Chaudhry, V., Arbuck, S. G.
and Donehower, R. C. (1993).Clinical toxicities encountered
with paclitaxel (Taxol). Semin. Oncol. 20, 1-15.
|
7 |
Sonnichsen, D. S., Liu, Q., Schuetz, E. G., Schuetz, J. D.,
Pappo, A. and Relling, M. V. (1995). Variability in human
cytochrome P450 paclitaxel metabolism. J. Pharmacol. Exp.
Ther. 27, 566-575.
|
8 |
Galati, G., Moridani, M. Y., Chan, T. S. and O’brien, P. J. (2001).
Peroxidative metabolism of apigenin and naringenin versus
luteolin and quercetin: glutathione oxidation and conjugation.
Free. Radical. Biology & Medicine. 30, 370-382.
DOI
|
9 |
Gao, P., Rush, B. D., Pfund, W. P., Huang, T., Bauer, J. M.,
Morozowich, W., Kuo, M. S. and Hageman, M. J. (2003).
Development of a supersaturable SEDDS (S-SEDDS)
formulation of paclitaxel with improved oral bioavailability. J.
Pharm. Sci. 92, 2386-2398.
DOI
|
10 |
Gates, M. A., Vitonis, A. F., Tworoger, S. S., Rosner, B.,
Titus-Ernstoff, L., Hankinson, S. E. and Cramer, D. W.
(2009). Flavonoid intake and ovarian cancer risk in a
population-based case-control study. Int. J. Cancer. 124,
1918-1925.
DOI
|
11 |
Harris, J. W., Rahman, A., Kim, B. R., Guengerich, F. P. and
Collins, J. M. (1994). Metabolism of taxol by human hepatic
microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res. 54,
4026-4035.
|
12 |
Ho, P. C., Saville, D. J. and Wanwimolruk, S. (2001). Inhibition
of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins
and related compounds. J. Pharm. Pharm. Sci. 4,
217-227.
|
13 |
Jeong, G. S., Lee, S. H., Jeong, S. N., Kim, Y. C. and Kim, E. C.
(2009). Anti-inflammatory effects of apigenin on nicotineand
lipopolysaccharide-stimulated human periodontal ligament
cells via heme oxygenase-1. Int. Immunopharmacol. 9,
1374-1380.
DOI
|
14 |
Kelly, P. A., Wang, H., Napoli, K. L., Kahan, B. D. and Strobel,
H. W. (1999). Metabolism of cyclosporine by cytochromes
P450 3A9 and 3A4. Eur. J. Drug. Metab. Pharmacokinet. 24,
321-328.
DOI
|
15 |
Kimura, Y., Ito, H., Ohnishi, R. and Hatano, T. (2010). Inhibitory
effects of polyphenols on human cytochrome P450 3A4 and
2C9 activity. Food. Chem. Toxicol. 48, 429-435.
DOI
|
16 |
Choi, J. S. and Li, X. (2005). The effect of verapamil on the
pharmacokinetics of paclitaxel in rats. Eur. J. Pharm. Sci. 24,
95-100.
DOI
|
17 |
Choi, J. S. and Shin, S. C. (2005). Enhanced paclitaxel bioavailability
after oral coadministration of paclitaxel prodrug with
naringin to rat. Int. J. Pharm. 292, 149-156.
DOI
|
18 |
Crespi, C. L., Miller, V. P. and Penman, B. W. (1997). Microtiter
plate assays for inhibition of human, drug-metabolizing
cytochromes P450. Anal. Biochem. 248, 188-190.
DOI
|
19 |
Choi, S. U., Lee, B. H., Kim, K. H., Choi, E. J., Park, S. H., Shin,
H. S., Yoo, S. E., Jung, N. P. and Lee, C. O. (1997). Novel
multidrug-resistance modulators, KR-30026 and KR-30031,
in cancer cells. Anticancer. Res. 17, 4577-4582.
|
20 |
Chuang, C. M., Monie, A., Wu, A. and Hung, C. F. (2009).
Combination of apigenin treatment with therapeutic HPV
DNA vaccination generates enhanced therapeutic antitumor
effects. J. Biomed. Sci. 27, 49-60.
|
21 |
Critchfield, J. W., Welsh, C. J., Phang, J. M. and Yeh, G. C.
(1994). Modulation of adriamycin accumulation and efflux by
flavonoids in HCT-15 colon cells. Activation of P-glycoprotein
as a putative mechanism. Biochem. Pharmacol. 48,
1437-1445.
DOI
|
22 |
Cummins, C. L., Jacobsen, W. and Benet, L. Z. (2002). Unmasking
the dynamic interplay between intestinal P-glycoprotein and
CYP3A4. J. Pharmacol. Exp. Ther. 300, 1036-1045.
DOI
|
23 |
Dixon, R. A. and Steele, C. L. (1999). Flavonoids and isoflavonoids
- a gold mine for metabolic engineering. Trends. Plant
Sci. 4, 394-400.
DOI
|
24 |
Fukuda, K., Ohta, T., Oshima, Y., Ohashi, N., Yoshikawa, M.
and Yamazoe, Y. (1997). Specific CYP3A4 inhibitors in
grapefruit juice: furocoumarin dimers as components of drug
interaction. Pharmacogenetics. 7, 391-396.
DOI
|
25 |
Choi, B. C., Choi, J. S. and Han, H. K. (2006). Altered
pharmacokinetics of paclitaxel by the concomitant use of
morin in rat. Int. J. Pharm. 323, 81-85.
DOI
|
26 |
Andreeva, M., Niedmann, P. D., Binder, L., Armstrong, V. W.,
Meden, H., Binder, M. and Oellerich, M. (1997). A simple and
reliable reverse-phase high-performance liquid chromatographic
procedure for determination of paclitaxel (taxol) in
human serum. Ther. Drug. Monit. 19, 327-332.
DOI
|
27 |
Berg, S. L., Tolcher, A., O’Shaughnessy, J. A., Denicoff, A. M.,
Noone, M., Ognibene, F. P., Cowan, K. H. and Balis, F. M.
(1995). Effect of R-verapamil on the pharmacokinetics of
paclitaxel in women with breast cancer. J. Clin. Oncol. 13,
2039-2042.
DOI
|
28 |
Cao, X., Gibbs, S. T., Fang, L., Miller, H. A., Landowski, C. P.,
Shin, H. C., Lennernas, H., Zhong, Y., Amidon, G. L., Yu, L.
X. and Sun, D. (2006). Why is it challenging to predict
intestinal drug absorption and oral bioavailability in human
using rat model. Pharm. Res. 23, 1675-1686.
DOI
|
29 |
Choi, J. S., Kim, Y. C. and Jo, B. W. (2004). Enhanced paclitaxel
bioavailability after oral administration of paclitaxel or prodrug
to rats pretreated with quercetin. Eur. J. Pharm. Biopharm.
57, 313-318.
DOI
|
30 |
Sparreboom, A., van Asperen, J., Mayer, U., Schinkel, A. H.,
Smit, J. W., Meijer, D. K., Borst, P., Nooijen, W. J., Beijnen,
J. H. and van Tellingen, O. (1997). Limited oral bioavailability
and active epithelial excretion of paclitaxel (Taxol) caused by
P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA. 4,
2031-2035.
|
31 |
van Asperen, J., van Tellingen, O., van der Valk, M. A.,
Rozenhart, M. and Beijnen, J. H. (1998). Enhanced oral
absorption and decreased elimination of paclitaxel in mice
cotreated with cyclosporine A. Clin. Cancer Res. 4, 2293-2297.
|
32 |
Yin, Y., Gong, F. Y., Wu, X. X., Sun, Y., Li, Y. H., Chen, T. and
Xu, Q. (2008). Anti-inflammatory and immunosuppressive
effect of flavones isolated from Artemisia vestita. J. Ethnopharmacol.
120, 1-6.
DOI
|
33 |
Walle, T., Walle, U. K., Kuma, G. N. and Bhalla, K. N. (1995).
Taxol metabolism and disposition in cancer patients. Drug
Metab. Disp. 23, 506-512.
|
34 |
Wani, M. C., Taylor, H. L., Wall, M. E., Coggon, P. and McPhail,
A. T. (1971). Plant antitumor agnets. VI. The isolation and
structure of taxol, a novel antileukemic and antitumor agent
from Taxus brevifolia. J. Am. Chem. Soc. 93, 2325-2327.
DOI
|
35 |
Woo, J. S., Lee, C. H., Shim, C. K. and Hwang, S. J. (2003).
Enhanced oral bioavailability of paclitaxel by coadministration
of the P-gp inhibitor KR30031. Pharm. Res. 20,
24-30.
DOI
|
36 |
Lee, S. H., Yoo, S. D. and Lee, K. H. (1999). Rapid and sensitive
determination of paclitaxel in mouse plasma by
high-performance liquid chromatography. J. Chomatogr. B.
Biomed. Sci. 724, 357-363.
DOI
|
37 |
Lewis, D. F. V. (1996). Cytochrome P450. Substrate specificity
and metabolism. In Cytochromes P450. Structure, Function,
and Mechanism (D. F. V. Lewis, Ed.), pp. 122-123. Taylor &
Francis, Bristol.
|